Fireside chat will be held on Monday, April 17, 2023, at 11:00 a.m. ET
NEW
HAVEN, Conn., April 11,
2023 /PRNewswire/ -- Trevi Therapeutics,
Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for the treatment of chronic cough in adults with
idiopathic pulmonary fibrosis (IPF) and other chronic cough
indications, and for the treatment of prurigo nodularis, today
announced that Jennifer Good,
President and Chief Executive Officer, Lisa
Delfini, Chief Financial Officer, and David Clark, MD, Chief Medical Officer, will be
participating in a fireside chat at the 22nd Annual
Needham Virtual Healthcare Conference on Monday, April 17,
at 11:00 a.m. ET. Ms. Good and Ms. Delfini will also
participate in investor meetings with attendees.
A live webcast will be accessible from the 'Investors &
News' section on the Company's website at
www.TreviTherapeutics.com. An archived replay of the webcast will
also be available for 30 days on the Company's website following
the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing Haduvio, an investigational therapy in an oral
extended-release formulation of nalbuphine, for the treatment of
chronic cough in IPF and other chronic cough indications. Haduvio
is a mixed ĸ-opioid receptor agonist and µ-opioid receptor
antagonist that works both centrally and peripherally. The ĸ and µ
receptors are known critical mediators of cough. Parenteral
nalbuphine has been approved and marketed for over 20 years for the
treatment of acute pain indications and is not scheduled by the DEA
in the United States or by
regulatory authorities in most of Europe. Trevi intends to propose Haduvio as
the trade name for nalbuphine ER. Its safety and efficacy have not
been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow the Company on Twitter and LinkedIn.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-the-22nd-annual-needham-virtual-healthcare-conference-301794624.html
SOURCE Trevi Therapeutics, Inc.